Journal of Allergy & Therapy

Bi(G)Med as a very novel method based on oral immunogenetical therapy to prevent and treat allergic diseases especially asthma

11^th International Conference on ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY

September 07-08, 2017 | Edinburgh, Scotland

Gilbert Glady

European Bio Immun(G)en Medecine Association, France

Scientific Tracks Abstracts: J Allergy Ther

Abstract:

Oral immunotherapy has become a recognized method and validated by numerous publications, and its use has developed in the current practice of an allergy clinic. It has also been identified as likely to result in fewer adverse reactions than other conventional treatments administered by the systemic route. We propose an innovative and even revolutionary methodology by some aspects still little known in common allergology, which allows a soft and progressive regulation of the main molecular disorders involved at an immunogenetic level in the pathophysiological mechanisms of the various allergic diseases currently listed. For this purpose, we first resort to a regulation taking place at the epigenetic level thanks to the introduction in our therapeutic methodology of microRNAs used for their remarkable posttranscriptional regulatory action. All components of our cures are prepared in high dilutions to avoid any noxious side effects and administered per sublingual way. But the Bio Immuno(G)en Medicine - BI(G)MED in shortcut - is also holistic in that it does not just act in a regulating way on the immunogenetic mechanisms involved directly in the genesis of allergic diseases, but also search for neutralizing infectious, viral and bacterial and even fungal agents, which have a pernicious influence on the course of clinical allergic phenomena. To achieve this result the BI(G)MED uses a wide range of biological tests to measure the patient's reaction potential at the immunogenetic level and the impact of infectious agents in direct interaction with the immune system. The description of clinical cases of my private practice with their therapeutic modalities will make it possible to highlight the regulatory properties of this new method referring to the self-regulation potential inherent in cellular homeostasis.

Biography :

Gilbert Glady has completed his MD from Strasbourg University of Medicine and Postdoctoral studies from Besançon and Paris-Nord Universities of Medicine. He got an expertise in immunology and immunogenetics during all these years and developed interest for alternative medicines. So in 2010, he became Creator of the BI(G)MED method and Director of EBMA, the European association for training the medical profession at the BI(G)MED. He has participated in numerous international congresses in the field of immuno-allergology, infectiology and oncology with posters and oral presentations.